Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence - PR Newswire

Singapore's health authority has updated the Wegovy (semaglutide) label to include a higher dose supported by STEP UP trial evidence, according to a PR Newswire release circulated via Google News. The regulatory move reflects growing international recognition of expanded dosing options for the GLP-1 peptide.

What the label update covers

The updated label incorporates a higher dosing tier for Wegovy, Novo Nordisk's branded semaglutide injection. According to the PR Newswire announcement, the revision is backed by evidence from the STEP UP clinical program, which evaluated the efficacy and safety profile of escalated semaglutide dosing.

Singapore's regulatory alignment follows similar reviews in other jurisdictions as demand for GLP-1 receptor agonists continues to outpace supply globally. The label change means prescribers in Singapore have formal guidance for the higher dose rather than relying on off-label escalation.

STEP UP evidence and regulatory context

The STEP UP trial program has been central to building the clinical case for expanded semaglutide dosing. While the full trial dataset is still being disseminated through peer-reviewed channels, the evidence was sufficient for Singapore's health authority to act.

• The label update applies specifically to Wegovy (semaglutide), not tirzepatide or other GLP-1/GIP dual agonists.
• STEP UP trial evidence served as the primary clinical basis for the regulatory revision.
• The update reflects a broader international trend of regulators revisiting GLP-1 dosing frameworks as real-world data accumulates.

Why this matters for the peptide market

Label expansions in individual markets matter because they create reference points for other regulators and shape prescribing norms. Singapore's decision adds to the momentum behind higher-dose GLP-1 protocols, which could influence compounding pharmacy standards, clinical guideline updates, and research peptide demand patterns in adjacent markets.

However, the development is still preliminary in the sense that full STEP UP publication and broader regulatory adoption remain in progress. SavePeptides will continue tracking label updates across jurisdictions as they emerge.

Sources